YAP1 and non-small cell lung carcinoma: YAP1 synergizes with dual specificity phosphatase 1 (DUSP1) to promote osimertinib resistance in NSCLC, and the YAP1/ TEA domain transcription factor (TEAD) axis has been identified as a driver of osimertinib resistance [9, 10].